|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Saraiya N, Yopp AC, Rich NE, Odewole M,
Parikh ND and Singal AG: Systematic review with meta-analysis:
Recurrence of hepatocellular carcinoma following direct-acting
antiviral therapy. Aliment Pharmacol Ther. 48:127–137. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lohitesh K, Chowdhury R and Mukherjee S:
Resistance a major hindrance to chemotherapy in hepatocellular
carcinoma: An insight. Cancer Cell Int. 18:442018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ventura A and Jacks T: MicroRNAs and
cancer: Short RNAs go a long way. Cell. 136:586–591. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhuo L, Liu J, Wang B, Gao M and Huang A:
Differential miRNA expression profiles in hepatocellular carcinoma
cells and drug-resistant sublines. Oncol Rep. 29:555–562. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bao CH and Guo L: Retracted: miR-27b-3p
inhibits invasion, migration and epithelial-mesenchymal transition
in gastric cancer by targeting RUNX1 and activation of the hippo
signaling pathway. Anticancer Agents Med Chem. 22:864–873. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li T, Wu Q, Liu D and Wang X: miR-27b
suppresses tongue squamous cell carcinoma epithelial-mesenchymal
transition by targeting ITGA5. Onco Targets Ther. 13:11855–11867.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Han M, Li N, Li F, Wang H and Ma L:
MiR-27b-3p exerts tumor suppressor effects in esophageal squamous
cell carcinoma by targeting Nrf2. Hum Cell. 33:641–651. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang G, Tian X, Li Y, Wang Z, Li X and
Zhu C: miR-27b and miR-34a enhance docetaxel sensitivity of
prostate cancer cells through inhibiting epithelial-to-mesenchymal
transition by targeting ZEB1. Biomed Pharmacother. 97:736–744.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C (T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen D, Si W, Shen J, Du C, Lou W, Bao C,
Zheng H, Pan J, Zhong G, Xu L, et al: miR-27b-3p inhibits
proliferation and potentially reverses multi-chemoresistance by
targeting CBLB/GRB2 in breast cancer cells. Cell Death Dis.
9:1882018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen X, Cui Y, Xie X, Xing Y, Yuan Z and
Wei Y: Functional role of miR-27b in the development of gastric
cancer. Mol Med Rep. 17:5081–5087. 2018.PubMed/NCBI
|
|
13
|
Feng Q, Wu X, Li F, Ning B, Lu X, Zhang Y,
Pan Y and Guan W: miR-27b inhibits gastric cancer metastasis by
targeting NR2F2. Protein Cell. 8:114–122. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun Y, Xu T, Cao YW and Ding XQ: Antitumor
effect of miR-27b-3p on lung cancer cells via targeting Fzd7. Eur
Rev Med Pharmacol Sci. 21:4113–4123. 2017.PubMed/NCBI
|
|
15
|
Luo Y, Yu SY, Chen JJ, Qin J, Qiu YE,
Zhong M and Chen M: MiR-27b directly targets Rab3D to inhibit the
malignant phenotype in colorectal cancer. Oncotarget. 9:3830–3841.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liang H, Ai-Jun J, Ji-Zong Z, Jian-Bo H,
Liang Z, Yong-Xiang Y and Chen Y: Clinicopathological significance
of miR-27b targeting Golgi protein 73 in patients with
hepatocellular carcinoma. Anticancer Drugs. 30:186–194. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sun XF, Sun JP, Hou HT, Li K, Liu X and Ge
QX: MicroRNA-27b exerts an oncogenic function by targeting Fbxw7 in
human hepatocellular carcinoma. Tumour Biol. 37:15325–15332. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
He S, Zhang J, Lin J, Zhang C and Sun S:
Expression and function of microRNA-27b in hepatocellular
carcinoma. Mol Med Rep. 13:2801–2808. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu Y, Han YF, Ye B, Zhang YL, Dong JD, Zhu
SJ and Chen J: miR-27b-3p is involved in doxorubicin resistance of
human anaplastic thyroid cancer cells via targeting peroxisome
proliferator-activated receptor gamma. Basic Clin Pharmacol
Toxicol. 123:670–677. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bai L, Lin Y, Xie J, Zhang Y, Wang H and
Zheng D: MiR-27b-3p inhibits the progression of renal fibrosis via
suppressing STAT1. Hum Cell. 34:383–393. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sharma SA, Kowgier M, Hansen BE, Brouwer
WP, Maan R, Wong D, Shah H, Khalili K, Yim C, Heathcote EJ, et al:
Toronto HCC risk index: A validated scoring system to predict
10-year risk of HCC in patients with cirrhosis. J Hepatol.
S0168-8278(17)32248-1. 2017.(Epub ahead of print).
|
